Teva Pharmaceutical Inc to discontinue a trial testing its drug for the treatment of chronic cluster headache

Israel’s Teva Pharmaceutical Inc said on Friday it would discontinue a trial testing its drug for the treatment of chronic cluster headache, after an analysis showed that the drug was unlikely to meet the study’s main goal. Cluster headaches occur in cyclical patterns, or clusters, and are among the most painful types of headaches.

The drug, fremanezumab, is under review by the U.S. Food and Drug Administration for prevention of migraines in adults and the company hopes to launch the drug for the disorder as soon as mid-September, reports Reuters.

Teva, which is counting on fremanezumab to help return to growth, also plans to continue testing the drug for the treatment of episodic cluster headaches.

“While we are disappointed with this outcome, we remain optimistic that fremanezumab could have clinical benefits in additional conditions, beyond migraine,” said Tushar Shah, senior vice president, head of global specialty clinical development at Teva.

Teva’s U.S.-listed shares fell 1.6 percent to $23.4 in premarket trading.


This article has been posted by a News Hour Correspondent. For queries, please contact through [email protected]
No Comments

Translate this News

Join the Facebook Group

Click here to join the Facebook group of News Hour

Popular Posts

Sacred Games exposes Rajshri Deshpande nude [video]
Yageo Corp to acquire Kemet Corp in a $1.8 billion deal
Four Spain attacks suspects to go before judge, eight others killed
Paperfly launches delivery services covering 64 districts in Bangladesh
Still a long way to go in T20 format for Bangladesh
Hong Kong police shoot protester as protests start working week


News of the Month

Scroll Up
%d bloggers like this: